DIAGNOS Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual Group
June 07 2022 - 11:44AM
DIAGNOS Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is pleased to announce the deployment of its
Age-Related Macular Degeneration detection application into the
optometry clinics of IRIS The Visual Group.
It is with great pleasure that DIAGNOS is
announcing the deployment of its Age-Related Macular Degeneration
(AMD) detection application into the optometry clinics of IRIS The
Visual Group (IRIS). With over 1,250 patients having received this
new test already, we can see that the demand is great for this
application in clinical optometry and optical retail. This
deployment of this application represents an important milestone in
the Artificial Intelligence Technology Implementation Program
announced in June 2021 by the two groups.
“We are thrilled by the addition of the AMD
detection application into our portfolio as it further expands the
value our company offers to eyecare providers, an important segment
of our market expansion strategy.” says Mr.
Yves-Stéphane Couture, Vice-President of DIAGNOS. “The
quality of the relationship we developed with IRIS throughout this
project and the constant spirit of collaboration and desire to
improve patient outcomes shared by our respective organizations
have been decisive in the development of this new tool, it
positively and directly contributed to the deployment we are doing
today.”
AMD is a leading cause of visual deterioration
and legal blindness in people over 60 years of age. The loss of
central vision and high-resolution visual acuity from untreated AMD
can lead to irreversible loss of reading, depression, reduced
facial recognition ability, and disqualification from driving.
Regular screening for eye diseases is of the utmost importance to
enable early detection of eye disease and prevent major alterations
in quality of life from occurring.
“The deployment of this new application in our
clinics is perfectly aligned with IRIS’ desire to be at the
forefront of technological advances in its clinical optometry and
optical retail operations. We strive to provide our customers with
the most effective cutting-edge technologies, with tools that
enhance the healthcare experience we provide and improve clinical
outcomes. Artificial Intelligence solutions like that of DIAGNOS
raise the bar in terms of quality of care and perfectly illustrate
of the benefits of our collaboration with this company.” said
Dr. Jahel St-Jacques, Optometrist and Vice-President of
IRIS.
DIAGNOS is currently putting the finishing
touches on several Artificial Intelligence Deep Learning algorithms
focused on disease detection and aimed to improve clinical
operations and patient outcomes. The launch of the AMD detection
application is the first in a series of important launches planned
soon, that will ensure the success and sustainability of the
organization.
About IRISIRIS was founded in 1990 in Quebec.
Since that time, IRIS has developed into the largest network of
optometrists, opticians and ophthalmologists operating under the
same banner across Canada. The company’s locations combine clinical
optometry and optical retail to provide a unique concept and a
commitment to offering top quality products and services in the
field of eyecare.
Additional information is available at
www.iris.ca
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available
at www.DIAGNOS.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: alarente@DIAGNOS.ca
Dr. Jahel St-Jacques, Optometrist, Vice-President Professional affairs and Partner relations
IRIS The Visual Group
Tel: 450-688-9060
Email: jahel.st-jacques@iris.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024